Drug Trial Radar · NCT05556863
Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
Oct 18, 2021
Primary completion
Nov 20, 2023
Study completion Nov 20, 2023
Sponsor
- Lead sponsor
- Electra Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.
Conditions
- Healthy Volunteers
Interventions
ELA026Drug
Single dose of ELA026
ELA026Drug
Multiple doses of ELA026
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability].Time frame: By week 3
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Medical University of Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.